Gestational Diabetes Drug Might Raise Babies' Complication Risk
Study links glyburide to more infant intensive care and respiratory distress
No abstract available
This study evaluated a novel composite measure of health literacy and numeracy by assessing its predictive validity for diabetes self-care activities and glycemic control. Methods: Patients (N = 102) with type 2 diabetes were recruited from a family medicine clinic at an academic medical center. Combined health literacy was assessed by combining the results of the Health Literacy Scale and the Subjective Numeracy Scale. Self-management activities were assessed by the Summary of Diabetes Self-Care Activities scale. Hemoglobin A1c (A1c) values were extracted from patients' medical records to assess glycemic control. Path ...
ConclusionsWeight loss after EGJR is sustained up to 5 years after revision with little effect on medical comorbidities. Patients with a greater reduction in stoma diameter experienced superior weight loss.
In this study, wound-related outcomes are examined, comparing patients who underwent surgery before (Group 1) versus after (Group 2) this intervention. Statistical analysis performed utilizingt tests and Chi square analysis;p
Publication date: May 2020Source: Social Science &Medicine, Volume 253Author(s): Roberto E. Montenegro, Gonen Dori-Hacohen
Purpose: Diabetes mellitus (DM) induces changes in corneal biomechanical properties. The influence of disease-specific factors was evaluated, and a novel DM index was created. Methods: Eighty-one patients with DM and 75 healthy subjects were matched according to age, intraocular pressure, and central corneal thickness. Information on the disease was collected, and measurements with the Ocular Response Analyzer and the Corvis ST were taken. Results were compared between the groups, and the influence of disease-specific factors was evaluated. From dynamic corneal response parameters, a DM index was calculated. Results:...
Conclusions: FAB in combination with conventional treatment may be successfully used in the management of refractory PEDs. No adverse effects arising from FAB treatment were observed.
Senseonics, makers of the first-ever implantable continuous glucose monitor Eversense, will no longer sell CGMs to new customers but for now will remain available to current users.
Publication date: July 2020Source: Biomedicine &Pharmacotherapy, Volume 127Author(s): Zhongyuan Wang, Yunfeng Zhu, Yanhua Zhang, Jie Zhang, Tianjiao Ji, Weizu Li, Weiping Li
Publication date: June 2020Source: Cancer Epidemiology, Volume 66Author(s): Wayne R. Lawrence, Akiko S. Hosler, Margaret Gates Kuliszewski, Matthew C. Leinung, Xiuling Zhang, Maria J. Schymura, Francis P. Boscoe